Lilly Furthers Precision Cancer Ambitions With Foghorn Collaboration

 
• By Joseph Haas

Building on its Loxo Oncology unit, Lilly teams with Foghorn to target cancers caused by BRG1 mutations, about 5% of all tumors, including 10% of NSCLC patients. Merck & Co. teamed up with Foghorn in 2020.

DNA
Lilly and Foghorn hope to find novel cancer approaches in DNA's compact structure

More from Deals

More from Business